Probe • Vol LXII • No. 3 • May–Aug 2023 • 19 Efficacy of Liv.52 in the Management of Infective Hepatitis and 8 weeks, the control group experienced a decline of 24% and 29%, respectively, as against 37% and 66%, respectively, in the Liv.52 group. SGPT and SGOT: The value of SGPT decreased by 38% and 71% in the control group and 53% and 82% in the Liv.52 group after 4 and 8 weeks of treatment, respectively (Table). The value of SGOT decreased to 48.2 units in the control group and 40.8 units in the Liv.52 group after 4 weeks of treatment. The average values of SGOT were 25.8 and 14 units in the control and Liv.52 groups, respectively, after 8 weeks of treatment. Histopathology: No histopathologic evidence of the disease was found in the Liv.52 group after 8 weeks. Conclusion The study results show that Liv.52 is more effective than the combination of vitamin B complex and corticosteroids alone. Liv.52 brings about early clinical improvement as well as promotes rapid and highly significant biochemical and histological improvements in infective hepatitis. Summary • In this controlled study, 50 patients, aged 15 to 65 years, with infective hepatitis were included. • A comparison of the liver function parameters showed that the improvement was significantly rapid after 4 to 8 weeks of treatment with Liv.52. • The results indicate that Liv.52 brought about early clinical improvement and promoted rapid and highly significant biochemical and histological improvements in infective hepatitis. Sources: Saxena A, et al. Ind J Exp Biol. 1979;7:662–664. Mandal JN, Roy BK. Probe. 1983;22(4):217–242. Singh KK, et al. Ind Med J. 1977;5:69. Table. A Comparison of the Improvements in the Biochemical Parameters in the Control and Liv.52 Groups Bilirubin SGPT SGOT Initial 8 wk Initial 8 wk Initial 8 wk Control Group (n = 25) 12.06 ± 0.7 4.81 ± 0.6 210.8 ± 10.1 60.6 ± 5.6 97.8 ± 5.8 25.8 ± 2.8 Liv.52 Group (n = 25) 12.8 ± 0.74 1.8 ± 0.04 219.6 ± 10.6 38.4 ± 2.6 99.94 ± 6.2 14.00 0.9 P Value NS < .01 NS < .01 NS < .01 NS, not significant; SGOT, serum glutamic oxaloacetic transaminase; SGPT, serum glutamic pyruvic transaminase. Conclusion The results demonstrated that treatment with Liv.52 provides protection against the decrease in the activity of the mitochondrial enzymes and aniline hydroxylase in CCl4-induced hepatotoxicity. Treatment with Liv.52 caused a decrease in CCl4induced hepatic lysosomal enzyme activity when compared with that in control rats. Summary • Liv.52 and the extract of S nigrum leaves (one of the constituents of Liv.52) were administered to weanling rats orally at a dose of 0.125 mL/kg body weight/day (equal to human dose) for 11 weeks. • Liv.52-fed rats showed significantly better growth during weeks 3 to 8 compared with S nigrum–fed rats or controls. • The activity of hepatic lysosomal enzymes— acid phosphatase, alkaline phosphatase, acid deoxyribonuclease, acid ribonuclease, and cathepsin B—was decreased in the Liv.52-fed rats compared with the control and S nigrum–fed rats. ...Continued from page 15 (Effect of Liv.52 on Hepatic Enzymes)
RkJQdWJsaXNoZXIy MjAwNDg=